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Background: No previous studies have compared the DPP-4 inhibitors vildagliptin and sitagliptin in terms of blood
glucose levels using continuous glucose monitoring (CGM) and cardiovascular parameters.
Methods: Twenty patients with type 2 diabetes mellitus were randomly allocated to groups who received
vildagliptin then sitagliptin, or vice versa. Patients were hospitalized at 1 month after starting each drug, and CGM
was used to determine: 1) mean (± standard deviation) 24-hour blood glucose level, 2) mean amplitude of
glycemic excursions (MAGE), 3) fasting blood glucose level, 4) highest postprandial blood glucose level and time, 5)
increase in blood glucose level after each meal, 6) area under the curve (AUC) for blood glucose level ≥180 mg/dL
within 3 hours after each meal, and 7) area over the curve (AOC) for daily blood glucose level <70 mg/dL. Plasma
glycosylated hemoglobin (HbA1c), glycoalbumin (GA), 1,5-anhydroglucitol (1,5AG), immunoreactive insulin (IRI),
C-peptide immunoreactivity (CPR), brain natriuretic peptide (BNP), and plasminogen activator inhibitor-1 (PAI-1)
levels, and urinary CPR levels, were measured.
Results: The mean 24-hour blood glucose level was significantly lower in patients taking vildagliptin than sitagliptin
(142.1 ± 35.5 vs. 153.2 ± 37.0 mg/dL; p = 0.012). In patients taking vildagliptin, MAGE was significantly lower
(110.5 ± 33.5 vs. 129.4 ± 45.1 mg/dL; p = 0.040), the highest blood glucose level after supper was significantly lower
(206.1 ± 40.2 vs. 223.2 ± 43.5 mg/dL; p = 0.015), the AUC (≥180 mg/dL) within 3 h was significantly lower after
breakfast (484.3 vs. 897.9 mg/min/dL; p = 0.025), and urinary CPR level was significantly higher (97.0 ± 41.6 vs.
85.2 ± 39.9 μg/day; p = 0.008) than in patients taking sitagliptin. There were no significant differences in plasma
HbA1c, GA, 1,5AG, IRI, CPR, BNP, or PAI-1 levels between patients taking vildagliptin and sitagliptin.
Conclusions: CGM showed that mean 24-h blood glucose, MAGE, highest blood glucose level after supper, and
hyperglycemia after breakfast were significantly lower in patients with type 2 diabetes mellitus taking vildagliptin
than those taking sitagliptin. There were no significant differences in BNP and PAI-1 levels between patients taking
vildagliptin and sitagliptin.
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The number of patients with type 2 diabetes mellitus is
rapidly increasing worldwide, especially in Asian coun-
tries, because of an aging population and changes in
dietary habits. The management of blood glucose levels
has become a significant medical issue. The short-term
aim of diabetes treatment is control of blood glucose
levels, and the long-term aim is avoidance of the compli-
cations of diabetes [1].
Glycosylated hemoglobin (HbA1c) level reflects the
blood glucose level over the preceding 2 months, and
can be used to diagnose diabetes or to evaluate blood
glucose control in patients known to be diabetic. Clinical
and observational studies have reported that reducing
HbA1c levels results in a lower incidence of cardiovas-
cular complications in diabetic patients with a shorter
time since diagnosis [2,3], but not in diabetic patients
with a longer time since diagnosis [4,5]. Starting treat-
ment for diabetes at an earlier stage is therefore thought
to be important for decreasing the risk of cardiovascular
events.
Current diabetes treatment programs aim to lower
HbA1c levels. However, recent clinical studies have
found that hypoglycemia and postprandial hypergly-
cemia are also associated with the development of car-
diovascular disease [6,7]. Treatment choices should
therefore consider control of variations in blood glucose
levels, as well as HbA1c levels, to reduce the risk of car-
diovascular events. Continuous glucose monitoring
(CGM) and self-monitoring of blood glucose routinely
record variations in blood glucose levels [8]. CGM can
evaluate changes in blood glucose levels, because it
allows recording over several days.
DPP-4 inhibitors are oral antihyperglycemic drugs that
have recently become available for diabetes treatment.
They enhance the actions of incretin, which promotes
insulin secretion and suppresses glucagon secretion de-
pending on blood glucose levels [9], thereby improving
blood glucose control without inducing hypoglycemia.
Various effects of incretin such as pancreatic β-cell pro-
tection and cardiovascular protection [10] are expected
to reduce the risk of development of cardiovascular dis-
eases. DPP-4 inhibitors are considered effective for the
treatment of type 2 diabetes mellitus in Asian patients,
including Japanese patients, who often have insufficient
insulin secretion [11,12], in contrast to Caucasian
patients who usually have insulin resistance. However,
few studies have examined differences in the control of
blood glucose levels between different DPP-4 inhibitors.
Sitagliptin and vildagliptin are known to have different
efficacy in suppressing DPP-4 activity. We conducted a
crossover pilot study named Jikei-Vildagliptin and sita-
gliptin with CGM TO Real blood glucose control in type
2 diAbetes (J-VICTORIA). This study compared theDPP-4 inhibitors vildagliptin and sitagliptin, using CGM
to evaluate blood glucose levels and analyze fluctuations
in blood glucose levels. We also compared cardiovascu-
lar parameters between patients taking vildagliptin and
sitagliptin by measuring plasma levels of brain natri-
uretic peptide (BNP) and plasminogen activator
inhibitor-1 (PAI-1).Subjects and methods
Subjects
Patients with type 2 diabetes mellitus who had poor con-
trol of blood glucose levels (HbA1c 6.5–9.5%) in spite of
diet and exercise therapy for 1 month or longer, with or
without oral antidiabetic treatment, were included in the
study. Exclusion criteria were: 1) type 1 diabetes melli-
tus, 2) severe ketosis, coma, or reduced level of con-
sciousness due to diabetes within the past 6 months, 3)
severe infection, pre- or postoperative, or severe trauma,
4) history of laparotomy or ileus, 5) chronic intestinal
disease associated with a disorder of digestion or absorp-
tion, 6) severe hernia, or stenosis or ulcer of the large
intestine, 7) pregnancy, possible pregnancy, or breast-
feeding, 8) moderate or severe renal dysfunction (cre-
atinine clearance <50 mL/min, serum creatinine level
≥1.5 mg/dL in men or ≥1.3 mg/dL in women), 9) severe
hepatic dysfunction, 10) insulin treatment, 11) treatment
with antidiabetic agents other than sulfonylureas, 12)
history of hypersensitivity to any of the ingredients of
the study drugs and 13) judged to be unsuitable for par-
ticipation for medical reasons. Patients were given
detailed explanations of the study protocol. Those who
provided informed consent were included in the study.
The study protocol was approved by the Ethical Com-
mittee of the Jikei University School of Medicine. The
Clinical Trial registration No. is UMIN000007687.Methods
Figure 1 shows a summary of the study protocol.
Patients were randomly allocated to the V/S or S/V
group at the beginning of study period. During Stage I,
the V/S group received vildagliptin 100 mg daily
(50 mg in the morning and 50 mg in the evening) and
the S/V group received sitagliptin 50 mg daily (in the
morning). This reflects the normal doses of these drugs
used in Japan. After 1 month of treatment, patients
were hospitalized for 4 days, and blood glucose levels
were measured for two consecutive days using CGM
(CGMS-gold; Medtronic Minimed, Northridge, CA,
USA). During Stage II, the V/S group received sitaglip-
tin (50 mg daily) and the S/V group received vildaglip-
tin (50 mg twice daily). After 1 month of Stage II
treatment, subjects were hospitalized for another 4 days
to measure blood glucose levels. Administration of
Hospitalization
CGM/blood examination/
urinalysis
Hospitalization
CGM/blood examination/
urinalysis
One month or longer 0 month 1month 2month
Observation period
Sitagliptin 50mg/day
vildagliptin 100mg/day
vildagliptin 100mg/day
Sitagliptin 50mg/dayV/SGroup
S/VGroup
Figure 1 Study protocol. After an outpatient observation period of 1 month or longer, patients were randomized to the V/S group which
initially received vildagliptin (50 mg twice daily) or the S/V group which initially received sitagliptin (50 mg once daily). The drugs were then
switched so that the V/S group received sitagliptin and the S/V group received vildagliptin. " indicates continuous glucose monitoring (CGM) on
the second and third hospital days. Identical meals were given to all patients during hospitalization.
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the study period.
The followings values were calculated using CGM
data: 1) mean 24-h (± standard deviation) blood glucose
level, 2) mean amplitude of glycemic excursions
(MAGE), 3) fasting blood glucose level, 4) highest post-
prandial blood glucose level and time, 5) increase in
blood glucose level after each meal, 6) area under the
curve (AUC) for blood glucose level ≥180 mg/dL within
3 h after each meal, and 7) area over the curve (AOC)
for daily blood glucose level <70 mg/dL.
Other data collected were plasma HbA1c, glycoalbu-
min (GA), 1,5-anhydroglucitol (1,5AG), immunoreactive
insulin (IRI), C-peptide immunoreactivity (CPR), BNP,
PAI-1, and 24-h urinary CPR levels. The subjects
ingested identical meals during hospitalization, and were
advised not to change their level of exercise.Statistical analysis
Data are shown as the mean± standard deviation. The
paired t-test was used to compare values between
patients taking different drugs, with the level of signifi-
cance set at p < 0.05. Statistical analysis of data was per-
formed using the Statistical Package for Social Sciences
software, version 19.0 (SPSS, Chicago, IL, USA).Table 1 Baseline patient characteristics
Characteristic Value
Age (years) 55.2 ± 15.5
Gender (M/F) 13/7
Body Mass Index (Kg/m2) 25.1 ± 5.4
Diabetes Duration (years) 4.5 ± 3.7
HbA1c (%) 7.9 ± 0.7
Treatment
None (diet/exercise) 12
SU 8
HbA1c = glycosylated hemoglobin; SU = sulfonylurea.Results
A total of 20 patients were enrolled in the study, with a
mean age of 55.2 ± 15.5 years, mean body mass index of
25.1 ± 5.4 kg/m2, mean HbA1c level of 7.9 ± 0.7%, and
mean time since diagnosis of diabetes of 4.5 ± 3.7 years.
Before enrollment in the study, 8 patients were taking a
DPP-4 inhibitor in combination with a sulfonylurea and
12 were taking a DPP-4 inhibitor only (Table 1). The
mean time since diagnosis of diabetes was relatively
short (4.5 years). None of the patients had clinical stage
IV peripheral arterial occlusive disease or lower limb
amputation.Variations in 24-h blood glucose levels measured by
CGM during treatment with sitagliptin and vildagliptin
are shown in Figure 2, and blood glucose indexes
derived from CGM results are shown in Table 2.
The mean 24-h blood glucose level was significantly
lower in patients taking vildagliptin than patients taking
sitagliptin (p = 0.012) during both the night (00:00 to
08:00) and the day (08:00 to 24:00). The standard devi-
ation of blood glucose levels was lower in patients taking
vildagliptin than patients taking sitagliptin, but this dif-
ference was not significant. MAGE was significantly
lower in patients taking vildagliptin than patients taking
sitagliptin (p = 0.040). Although there was no significant
difference in preprandial glucose levels between drugs,
both the highest postprandial glucose level within 3 h
(peak value) and the amplitude of increase in glucose
level (the difference between the preprandial value and
the peak value within 3 h) were lower in patients taking
vildagliptin than patients taking sitagliptin after each
meal. The peak value after dinner was significantly lower
in patients taking vildagliptin than patients taking sita-
gliptin (p = 0.015). There was no difference in the time
taken to reach the highest postprandial glucose level be-
tween patients taking vildagliptin and patients taking
sitagliptin.
Figure 2 Glucose levels over 24 h during treatment with vildagliptin or sitagliptin in 20 patients. Data are mean± standard deviation.
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each of breakfast, lunch, and dinner in patients taking
vildagliptin than patients taking sitagliptin, and this dif-
ference was significant after breakfast (p = 0.025). The
AOC (<70 mg/dL) was comparable for vildagliptin (95.6
mg/min/dL) and sitagliptin (16.2 mgmin/dL).
There were no differences between in plasma HbA1c,
GA, and 1,5-AG levels, which are indexes of blood glu-
cose control, between patients taking vildagliptin and
patients taking sitagliptin. There was no significant
change in mean body weight in either group during the
study period.
There were also no differences in plasma BNP, PAI-1,
IRI, or CPR levels between patients taking vildagliptin
and patients taking sitagliptin, but the urinary CPR level
was significantly higher in patients taking vildagliptin
than patients taking sitagliptin (p = 0.008) (Table 3).
Discussion
The influence of the DPP-4 inhibitors vildagliptin
(100 mg daily) and sitagliptin (50 mg daily) on blood
glucose levels in patients with type 2 diabetes mellitus
was investigated in this crossover study. Mean 24-h
blood glucose level and MAGE were significantly lower
in patients taking vildagliptin than patients taking
sitagliptin.
Differences in drug efficacy between vildagliptin and
sitagliptin have been investigated in a few studies. A
comparison of the randomized trials conducted in Japan
showed that vildagliptin 100 mg daily resulted in lower
HbA1c levels (by approximately 0.3%) than sitagliptin
50 mg daily [13]. A meta-analysis of studies using dosesbetween 50 mg and 100 mg for both drugs found that
the efficacy of vildagliptin and sitagliptin were compar-
able [14,15].
Kishimoto et al. reported that sitagliptin effectively
reduced postprandial blood glucose fluctuations and sta-
bilized blood glucose levels [16]. Sitagliptin may also
work as a vasoprotective agent in diabetes by blocking
the AGE-RAGE axis [17]. Marfella et al. compared vilda-
gliptin (100 mg daily) and sitagliptin (100 mg daily)
using CGM, and reported a better MAGE in the vilda-
gliptin group, although there was no difference in mean
24-h blood glucose level between the groups [18]. Rizzo
et al. reported recently that reductions in oxidative stress
and markers of systemic inflammation were greater in
patients with type 2 diabetes taking vildagliptin than
those taking sitagliptin [19]. These results were obtained
in Caucasian patients, and it important to also compare
the effects of these drugs in Asian patients, including
Japanese patients, because there are differences in causes
of diabetes, insulin secretion, and background character-
istics between Caucasian and Japanese patients.
The reason for the differences in drug efficacy (mean
blood glucose level and MAGE) observed in this study is
considered to be that sitagliptin 50 mg daily results in
less than 70% suppression of DPP-4 activity over 24 h
[20] whereas vildagliptin 50 mg twice daily results in
80% or greater suppression of DPP-4 activity over 24 h
[21]. It is also possible that the different mode of binding
with DPP-4 and the different frequency of drug adminis-
tration results in a greater reduction in blood glucose
level after supper and breakfast in patients taking vilda-
gliptin [22].
Table 3 Glucose and cardiovascular parameters in
patients taking vildagliptin (100 mg daily) or sitagliptin
(50 mg daily)
vildagliptin sitagliptin p-value
HbA1c (%) 7.54 ± 0.93 7.64 ± 0.93 0.211
GA (%) 19.8 ± 3.47 20.1 ± 3.31 0.087
1,5AG (μg/mL) 7.68 ± 5.60 7.49 ± 6.16 0.389
IRI (μU/mL) 7.26 ± 4.44 6.94 ± 4.37 0.735
CPR (ng/mL) 2.14 ± 0.92 1.95 ± 0.78 0.302
U-CPR (μ/day) 97.0 ± 41.6 85.2 ± 39.9 0.008*
BNP (pg/mL) 7.00 ± 9.24 8.03 ± 8.40 0.283
PAI-1 (ng/mL) 36.6 ± 14.9 40.6 ± 23.1 0.231
GA=glycoalbumin; 1,5-AG= 1,5-anhydroglucitol; IRI = immunoreactive insulin;
CPR =C-peptide immunoreactivity; BNP=brain natriuretic peptide; PAI-
1 = plasminogen activator inhibitor-1.
Data are mean ± standard deviation. Paired-sample t-test. * p < 0.05.
Table 2 Parameters of glucose variability in patients taking vildagliptin (100 mg daily) or sitagliptin (50 mg daily)
Vildagliptin Sitagliptin P-value
24-h mean glucose level (mg/dL) 142.1 ± 14.0 153.2 ± 29.7 0.012*
0:00 to 08:00 (night) mean glucose level (mg/dL) 117.4 ± 22.1 130.9 ± 26.3 0.042*
08:00 to 24:00 (day) mean glucose level (mg/dL) 154.1 ± 25.6 164.4 ± 35.3 0.043*
SD over 24 h (mg/dL) 35.5 ± 12.6 37.0 ± 13.9 0.542
Preprandial glucose level (mg/dL) 110.5 ± 33.5 129.4 ± 45.1 0.040*
Preprandial glucose level (mg/dL) 128.1 ± 16.2 133.5 ± 26.8 0.282
lunch 109.1 ± 22.2 120.9 ± 44.8 0.165
Highest postprandial glucose level within 3 hours after each meal (mg/dL) 112.4 ± 21.1 116.6 ± 24.7 0.221
Highest postprandial glucose level within 3 hours after each meal (mg/dL) 211.0 ± 40.0 228.0 ± 58.4 0.117
lunch 188.6 ±37.7 203.1 ± 50.3 0.172
supper 206.1 ± 40.2 223.2 ± 43.5 0.015*
Time from start of meal to the highest postprandial glucose level (minutes)
breakfast 76.0 ± 18.0 86.0 ± 28.4 0.204
lunch 93.3 ± 30.2 99.0 ± 35.6 0.579
supper 81.8 ± 24.6 93.0 ± 26.4 0.223
Differences between preprandial and highest postprandial glucose level for each meal (mg/dL)
breakfast 83.0 ± 37.1 94.5 ± 46.3 0.185
lunch 79.5 ± 31.8 82.3 ± 33.9 0.774
supper 93.7 ± 35.7 106.6 ± 43.2 0.065
AUC (≧180 mg/dL) for glycemic variability within 3 h of each meal (mgmin/dL)
breakfast 484.3 ± 541.1 897.9 ± 1097 0.025*
lunch 306.0 ± 554.8 630.5 ± 1017.2 0.152
supper 523.5 ± 618.3 703.4 ± 676.4 0.106
AOC (<70 mg/dL) for glycemic variability in 24 h(mgmin/dL)
95.6 ± 243.0 16.2 ± 61.2 0.183
Data are mean ± standard deviation. Paired-sample t-test. * p < 0.05.
AUC= area under the curve; AOC= area over the curve.
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pression of glucagon secretion by the evening dose leads
to a lower AUC (≥180 mg/dL) after breakfast, and sup-
pression of glucagon secretion by the morning dose
leads to a lower peak in blood glucose level after supper.
These results seem to support a twice daily administra-
tion schedule for vildagliptin.
Postprandial hyperglycemia has been reported to trig-
ger vascular disorders and cause cardiovascular events,
and is more common in patients with high HbA1c levels
[23]. Selection of a DPP-4 inhibitor that effectively sup-
presses postprandial hyperglycemia contributes to the
maintenance of ideal HbA1c levels.
It is interesting that urinary CPR level and variations
in blood glucose level were higher in patients taking vil-
dagliptin than patients taking sitagliptin. We postulate
that the higher level of DPP-4 inhibition over 24 h in
patients taking vildagliptin, compared with patients tak-
ing sitagliptin, inhibits the destruction of incretin, which
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ing MAGE and achieving a more stable reduction in
blood glucose levels. A relationship between MAGE and
oxidation stress has also been reported [24], suggesting
that improvement of MAGE by vildagliptin administra-
tion might suppress oxidation stress and decrease the in-
cidence of adverse cardiovascular events in the long
term. This possibility should be further elucidated in fu-
ture studies.
As DPP-4 inhibitors are reported to lower BNP level
[25], and vildagliptin is reported to suppress PAI-1 pro-
duction [26], this study measured BNP and PAI-1 levels
to evaluate cardiovascular parameters, but no differences
were observed between patients taking vildagliptin and
sitagliptin. Linagliptin, other DPP-4 inhibitor, has been
reported to be beneficial in terms of cardiac protection
and safety [27]. Improvements in parameters might be
due to the effects of the drugs, but results might also be
affected by factors such as the number of subjects, short
treatment period, and the blood glucose levels being
within the normal range.
This study has limitations as a pilot study because of
the small number of subjects and the sitagliptin dose of
50 mg. A randomized, double-blind, placebo-controlled
study of sitagliptin performed in Japanese patients
reported that HbA1c was reduced by 0.71% after oral
administration of sitagliptin 50 mg daily for 12 weeks,
and by 0.69% after oral administration of sitagliptin
100 mg daily for 12 weeks, which was not a significant
difference [28]. It is not known if using a dose of sita-
gliptin 100 mg daily in this study would have signifi-
cantly affected the results. The results of larger clinical
trials evaluating the cardiovascular protective effects and
safety of DPP-4 inhibitors are awaited.Conclusion
Vildagliptin 50 mg administered twice daily to patients
with type 2 diabetes mellitus significantly lowered the
mean 24-h blood glucose level measured by CGM,
MAGE, the highest blood glucose levels after dinner,
and hyperglycemia after breakfast, compared with sita-
gliptin 50 mg administered once daily. There were no
significant differences in BNP and PAI-1 levels between
patients treated with vildagliptin and sitagliptin.
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